8.GALACTOSE-ALPHA-1, 3-GALACTOSE-CONTAINING N-GLYCANS IN GLYCOPROTEIN PRODUCTS DERIVED FROM CHO CELLS
Abstract: The present invention provides methods for evaluating a Chinese Hamster Ovary (CHO) cell population by measuring glycans containing terminal galactose-alpha-1-3-galactose residues produced by said cells, wherein the CHO cells have not been genetically engineered to express an alpha-galactosyl transferase coding sequence.
Abstract: The present disclosure provides methods of making isotopically-labeled glycans or a mixture of glycans (e.g., a glycan preparation) via reductive amination. Such methods are useful, for example, in the determination of the relative amounts of a glycan species present in two or more glycoprotein preparations using mass spectroscopy. In one aspect, the present disclosure provides a method of making an isotopically-labeled glycan by a glycan with an amine and an isotopically-labeled reducing agent to provide an isotopically-labeled aminated glycan. In certain embodiments, the amine is an isotopically-labeled amine.
Over 100 patents give Momenta a strong proprietary position. Momenta possesses a strong intellectual property position around our characterization platform. We license or own a total of over 100 patents and patent applications. Our patent portfolio includes claims covering:
•methods and technologies for characterizing sugars; •the use of certain enzymes and reagents that specifically recognize polysaccharides in the characterization of sugars; •methods and technologies for chemical and metabolic synthesis of sugars; •the composition of matter of certain novel low-molecular-weight herapins (LMWHs), including M118, and heparinase variants; •methods to produce and identify sugars associated with glycoproteins; •methods to analyze and monitor glycoprotein profiles for purposes associated with the diagnosis, staging, prognosis and monitoring of cancer; and •methods for the in vivo non-invasive delivery of sugars. We also rely on trade secrets, know-how, continuing technological innovation and in-licensing opportunities to develop and maintain our proprietary position
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.